Book chapter
Cell-Bound Complement Activation Products (CB-CAPs) as a Source of Lupus Biomarkers
Current Topics in Complement, pp 381-390
2006
PMID: 16893085
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Measurement of serum C3 and C4 has been used for several decades to monitor disease activity in patients with SLE. Despite the limited utility and recognized weaknesses of these assays, they have remained the gold standard during an era of unprecedented discovery in the complement field. The current urgent need for lupus biomarkers warrants efforts to mine the complement system for assays superior to serum C3 and C4. Recent studies of soluble and cell-bound complement activation products hold promise for achieving this goal.
Metrics
Details
- Title
- Cell-Bound Complement Activation Products (CB-CAPs) as a Source of Lupus Biomarkers
- Creators
- Sarah J. Calano - University of PittsburghPei-an B. Shih - University of PittsburghChau-Ching Liu - University of Pittsburgh School of MedicineAmy H. Kao - University of PittsburghJeannine S. Navratil - University of PittsburghSusan Manzi - University of PittsburghJoseph M. Ahearn - University of Pittsburgh
- Contributors
- John D. Lambris (Editor)
- Publication Details
- Current Topics in Complement, pp 381-390
- Series
- Advances in Experimental Medicine and Biology
- Publisher
- Springer US; Boston, MA
- Number of pages
- 10
- Resource Type
- Book chapter
- Language
- English
- Academic Unit
- Medicine (Graduate); General Internal Medicine
- Web of Science ID
- WOS:000239508000025
- Scopus ID
- 2-s2.0-84934440061
- Other Identifier
- 991021934005204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Biochemistry & Molecular Biology
- Immunology
- Medicine, Research & Experimental